← Eichor
Condition: Recurrent Grade 3A Follicular Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Recurrent Grade 3A Follicular Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Tri
Phase 2 · 1 location(s) · University of Washington · NCT06948786Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Ly
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06453044Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06859008
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.